Tag: Pharma Strategy
EU-HTA 2026 Reality Check: What Pharma Must Get Right on JCA, RWE and Market Access
EU-HTA 2026 Reality Check: What Pharma Must Get Right on JCA, RWE and Market Access The European Union’s Health Technology Assessment framework is transforming how pharmaceutical companies prepare clinical evidence, demonstrate therapeutic value and plan market access across Europe. As Joint Clinical Assessment (JCA) implementation progresses, manufacturers face growing pressure to align clinical development, Real-World…
From Evidence Generation to Market Access: Why Integrated Evidence Planning Is Pharma’s Competitive Advantage Under EU HTA
From Evidence Generation to Market Access: Why Integrated Evidence Planning Is Becoming Pharma’s Competitive Advantage Under EU HTA How cross-functional collaboration, Real-World Evidence, AI, and early planning are reshaping successful market access strategies across Europe. The European pharmaceutical landscape is changing rapidly. Over the past year, discussions around the EU Health Technology Assessment (HTA) Regulation…
Strategic Insight into RWE Scalability for Pharmaceutical Firms
Strategic Insight into RWE Scalability for Small & Large Pharmaceutical Firms The global pharmaceutical industry is undergoing a fundamental transformation, driven by data-rich healthcare ecosystems, regulatory reforms, and the shift toward patient-centric models. At the heart of this transformation lies Real World Evidence (RWE), a tool that is no longer optional but a strategic necessity.…
